Skip to main content
2025
Corporate

The Board established the Audit and Risk Committee in compliance with section 45 of the PGPA Act and section 17 of the Public Governance, Performance and Accountability Rule. Its primary role is to assist the Board to discharge its responsibilities in respect of financial reporting, performance reporting, risk oversight and management, internal control and compliance with relevant laws and policies.

2019
Publication or report

In 2019, Professor Lynne Emmerton led the review of name similarity for:

  • Monoclonal antibodies (MABs) (commonly ending in the suffix ‘mab’)
  • Tyrosine kinase (factor) inhibitors (TKIs) (commonly ending in the suffix ‘nib’).

This included the theoretical risk of confusion within these classes of medicines in clinical practice, including the similarity in clinical indication, with a view to producing a specialised list of medicines. The results of this review can be found in this publication.

Back to top